Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Standard Biotools (LAB) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Standard Biotools (LAB) over the last 16 years, with Q3 2025 value amounting to $10.1 million.

  • Standard Biotools' Cost of Revenue rose 108.43% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.7 million, marking a year-over-year increase of 7116.25%. This contributed to the annual value of $90.2 million for FY2024, which is 6133.48% up from last year.
  • Per Standard Biotools' latest filing, its Cost of Revenue stood at $10.1 million for Q3 2025, which was up 108.43% from $11.1 million recorded in Q2 2025.
  • Over the past 5 years, Standard Biotools' Cost of Revenue peaked at $57.5 million during Q4 2024, and registered a low of $10.0 million during Q3 2024.
  • For the 5-year period, Standard Biotools' Cost of Revenue averaged around $16.4 million, with its median value being $14.1 million (2023).
  • Data for Standard Biotools' Cost of Revenue shows a peak YoY increase of 28746.54% (in 2024) and a maximum YoY decrease of 2992.33% (in 2024) over the last 5 years.
  • Standard Biotools' Cost of Revenue (Quarter) stood at $15.6 million in 2021, then grew by 1.66% to $15.9 million in 2022, then decreased by 6.45% to $14.8 million in 2023, then surged by 287.47% to $57.5 million in 2024, then tumbled by 82.48% to $10.1 million in 2025.
  • Its last three reported values are $10.1 million in Q3 2025, $11.1 million for Q2 2025, and $21.1 million during Q1 2025.